Cimidahurinine can attenuate Doxorubicin (DOX)-induced cardiotoxicity in a dose-dependent manner with EC50 values of 45.79 uM; it protects against cardiotoxicity by decreasing reactive oxygen species (ROS) accumulation and downregulating apoptosis-related Bax Bcl-2 proteins.
Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1 2, PI3K, and PKC are involved in this effect.Cimiside E may be an effective chemopreventive agen
7,8-Didehydrocimigenol can be used for the treatment of cardiovascular disorders such as atherosclerosis. It upregulates PPAR-γ in EC inhibits NF-kB activity of TNF-α-activated EC which leads to selective inhibition of VCAM-1 expression.
Cimigenol is a potential antitumor compound, combination of it with an autophagy inhibitor may be a valuable strategy for the chemoprevention or treatment of colon cancer. It exerted potent cytotoxic activity against SMMC-7721 (7.87μM) and A-549 (12.16 μM